merpan 80wg
adama - grânulos dispersíveis em água (wg) - captana 80% wg - controlo de doenças
merpan 480 sc
adama - suspensão concentrada (sc) - 480 g/l ou 39% (p/p) de captana - controlo de doenças
garbol
bayer ag - concentrado para emulsão (ec) com 790 g/l de óleo parafínico - hidrocarboneto
lemtrada
sanofi belgium - alemtuzumab - esclerose múltipla - imunossupressores seletivos - lemtrada é indicado para pacientes adultos com esclerose múltipla remitente-remitente (rcms) com doença ativa definida por características clínicas ou de imagem.
tysabri
biogen netherlands b.v. - natalizumab - esclerose múltipla - imunossupressores seletivos - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 e 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.
cimetidina
laboratÓrio teuto brasileiro s/a - cimetidina - antiulcerosos
nexavar
bayer s.a. - tosilato de sorafenibe - antineoplasico
milid 300 mg cápsula
bgp products, unipessoal lda. - erdosteína - cápsula - 300 mg - erdosteína 300 mg - erdosteine - n/a - duração do tratamento: curta ou média duração
milid 300 mg comprimido dispersível
bgp products, unipessoal lda. - erdosteína - comprimido dispersível - 300 mg - erdosteína 300 mg - erdosteine - n/a - duração do tratamento: curta ou média duração
tyruko
sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - imunossupressores - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 e 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.